Policy & Regulation
Bioharmony Therapeutics signs collaborative research and licensing agreement with Boehringer Ingelheim
17 January 2019 -

Bioharmony Therapeutics, a biopharmaceutical company focusing on the development of novel therapeutics for hard to treat bacterial infections, has signed a collaborative research and licensing agreement with Boehringer Ingelheim, it was reported yesterday.

The contract has been signed to develop bacteriophage lysins for the treatment of multidrug resistant Acinetobacter infections, a frequent cause of hospital-acquired pneumonia and life-threatening blood or wound infections.

Bioharmony licensed this technology from the Rockefeller University. The discoveries are from the laboratory of Vincent A Fischetti, PhD, a faculty member at The Rockefeller University. Recently, the World Health Organisation listed drug-resistant Acinetobacter baumannii to be a critical priority pathogen, causing around 9% of all bacterial infections in intensive care worldwide, against which there are few treatment options available.

Financial terms of the deal have not been revealed.

Login
Username:

Password: